We defined remission as the absence of clinical symptoms with a radiological confirmation of EUF closure. Multivariate Cox regression analysis was performed to determine factors predictive of achieving remission without need for surgery. Results: Thirty-three patients received anti-TNF therapy (21 infliximab, 9 adalimumab and 3 both) and were included in the study. Twenty-five (75%) patients were male. Mean (SD) age at diagnosis of EUF was 33 (13) years and median disease duration was 31 months (IQR 12–97). Seventeen patients (51%) were treated concomitantly with buy Pembrolizumab an immunomodulator (IMM). Fifteen patients (45%) achieved sustained remission (median follow-up from remission 34 months, IQR 18–44) without

needing surgery (10 with infliximab and 4 with adalimumab) and 14 of these continued on anti-TNF therapy. A further 15 (45%) patients achieved CP 690550 sustained remission after surgery (median follow-up 59 months; IQR 26–74). Three patients were in partial response at the last follow-up visit and continued on anti-TNF therapy. In the Cox analysis (adjusted for age, gender, fecaluria and/or pneumaturia, concomitant IMM or antibiotics and type of anti-TNF), only patients with concomitant IMM showed a tendency towards an increased rate of remission without need for surgery (HR 0.42, 95%CI 0.16–1.12; p < 0.08). Conclusion: Anti-TNF therapy

was effective for EUFs in CD, with 45% of patients achieving sustained remission without need for surgery. Therefore anti-TNF therapy seems to be a useful treatment for EUF in CD patients in whom the aim is to avoid surgery. There was a trend in favour of the concomitant use of IMM. Key Word(s): 1. enterourinary fistula; 2. Crohn′s diesease; 3. infliximab; 4. adalimumab; Presenting Author: JINHUI WANG Additional Authors: WENJI CHEN, JIE CHEN, MINHU CHEN Corresponding Author: JINHUI WANG Affiliations: the fisrt affiliated hospital of Sun Yatsen University Objective: Background: The pathogenesis of autoimmune hepatitis (AIH) is poorly understood. The AIH model

in mice induced with hapten S100 and adjuvant has been developed to elucidate the mechanisms. Syngeneic hapten S100 is a crude protein compound, from which three peak proteins STK38 (peak I, peak II and peak III protein) can be separated. There is a hypothesis suggesting that these separated peak proteins derived from hapten S100 may be involved in the immunological reactions through T-cell pathway in experimental autoimmune hepatitis (EAIH). Objective: To test the effect of hapten S100 and its three peak proteins on immunological reactivity of EAIH in mouse models. Methods: Methods: EAIH models in C57BL/6 mice were induced with syngeneic hapten S100 liver proteins and its three separated peak proteins emulsified covalently in complete Freund’s adjuvant (CFA) through intraperitoneal injection once a week for 4 weeks. CFA alone and saline were used as controls (5 mice in each group, altogether 6 groups).